OncoCyte (NASDAQ:OCX) Research Coverage Started at StockNews

StockNews.com initiated coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a report published on Friday morning. The firm issued a sell rating on the stock. Separately, Needham & Company LLC decreased their target price on shares of OncoCyte from $1.40 to $0.45 and set a buy rating for the company in a research […]

Related Keywords

United States , , Pura Vida Investments Llc , Goldman Sachs Group Inc , Oncocyte Company Profile , Needham Company , Cubist Systematic Strategies , Oncocyte Corporation , Raymond James Financial Services Advisors Inc , Free Report , Pura Vida Investments , James Financial Services Advisors , Sachs Group , Systematic Strategies , Cyte Corporation , Oncocyte Daily ,